Nebivolol therapy and reduction of intravascular platelet activity in patients with atrial hypertension and metabolic syndrome
Aim. To assess nebivolol clinical effects on intravascular platelet activity in patients with arterial hypertension (AH) and metabolic syndrome (MS). Material and methods. In total, 21 patients were administered nebivolol (5 mg/d) for one month. Dynamics of anthropometry parameters, lipid profile, p...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2006-06-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1203 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aim. To assess nebivolol clinical effects on intravascular platelet activity in patients with arterial hypertension (AH) and metabolic syndrome (MS). Material and methods. In total, 21 patients were administered nebivolol (5 mg/d) for one month. Dynamics of anthropometry parameters, lipid profile, plasma and platelet lipid peroxidation, blood an platelet antioxidant potential, and intravascular platelet activity, was evaluated. Results. In patients with AH and MS, nebivolol reduced lipid peroxidation and intravascular platelet activity. Longterm therapy could enhance these beneficial effects. Conclusion. To reduce body weight in patients with AH and MS, nebivolol should be combined with nonpharmaceutical methods. |
|---|---|
| ISSN: | 1728-8800 2619-0125 |